Nefrologia最新文献

{"title":"Analysis of the association between Healthy Eating Index (HEI)-2020 and diabetic kidney disease in type 2 diabetes patients: Based on the NHANES database","authors":"Chunping Dong,&nbsp;Hui Li,&nbsp;Jing Li,&nbsp;Yuan Qiao,&nbsp;Shan Gao","doi":"10.1016/j.nefro.2025.501452","DOIUrl":"10.1016/j.nefro.2025.501452","url":null,"abstract":"<div><h3>Background</h3><div>A rise in the Healthy Eating Index (HEI) 2020 is associated with a reduced risk of chronic kidney disease. However, it remains unclear whether HEI-2020 exhibits a similar positive effect in diabetic patients.</div></div><div><h3>Objectives</h3><div>This work aimed to investigate the relationship between HEI-2020 and the prevalence of diabetic kidney disease (DKD) in type 2 diabetes (T2D) patients.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis was based on the National Health and Nutrition Survey database from 2007 to 2018. A weighted logistic regression model, restricted cubic splines, and subgroup analysis were undertaken to assess the relationship between HEI-2020 and the prevalence of DKD in T2D patients. A weighted logistic regression model and a weighted quantile sum (WQS) regression model were employed. The independent impact of HEI-2020-related components on the prevalence of DKD among T2D patients was analyzed. In addition, sensitivity analysis was conducted.</div></div><div><h3>Results</h3><div>A total of 4255 participants with T2D were enrolled, with a DKD prevalence rate of 34.7%. The logistics regression analysis demonstrated a significant inverse relation between the HEI-2020 score and the prevalence of DKD in fully adjusted models (OR<!--> <!-->=<!--> <!-->0.982, 95% CI: 0.973–0.992, <em>P</em> <!-->&lt;<!--> <!-->0.001). No nonlinear relationship was detected (<em>P</em>-non-linear<!--> <!-->=<!--> <!-->0.970). No subgroup with significant interaction was identified. The WQS regression indicated that in fully adjusted models, the WQS index for HEI-2020 was significantly negatively correlated with the prevalence of DKD among T2D patients (OR<!--> <!-->=<!--> <!-->0.765, 95% CI: 0.621–0.943, <em>P</em> <!-->=<!--> <!-->0.012), with dairy products, total protein foods, and total vegetables as the most influential components. In addition, HEI-2020 was significantly negatively correlated with DKD in previously diagnosed T2D patients (OR<!--> <!-->=<!--> <!-->0.979, 95% CI: 0.967–0.990, <em>P</em> <!-->&lt;<!--> <!-->0.001), while no significant association was observed in newly diagnosed patients. The sensitivity analysis yielded similar results, indicating that our results were robust.</div></div><div><h3>Conclusion</h3><div>This research revealed a relationship between an increase in the HEI-2020 score and a lower prevalence of DKD among T2D patients, emphasizing the importance of the intake of dairy products, total protein foods, and total vegetables. This finding provides new scientific grounds for dietary management in T2D patients.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501452"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uso en vida real de patirómero en pacientes con hiperpotasemia: estudio retrospectivo en la Comunidad Valenciana","authors":"Francesc Moncho-Francés ,&nbsp;Boris Gonzales-Candia ,&nbsp;José Perez-Silvestre ,&nbsp;Miriam Sandin ,&nbsp;Pilar Sanchez-Perez ,&nbsp;Rafael Garcia-Maset ,&nbsp;Jonay Pantoja ,&nbsp;Juan Antonio Carbonell-Asins ,&nbsp;Elena Gimenez-Civera ,&nbsp;Rafael De la Espriella ,&nbsp;María Jesús Puchades ,&nbsp;Julio Nuñez ,&nbsp;José Luis Górriz","doi":"10.1016/j.nefro.2025.501454","DOIUrl":"10.1016/j.nefro.2025.501454","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hyperkalaemia is common in patients with chronic kidney disease (CKD) treated with renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs). Although new potassium binders have demonstrated efficacy in clinical trials, evidence from real-world clinical practice remains limited.</div></div><div><h3>Materials and methods</h3><div>We present a retrospective, observational, multicentre, non-interventional study aimed at evaluating the use of patiromer in patients with hyperkalaemia under routine clinical conditions in the Valencian Community. Patients who received patiromer for at least 3 months due to hyperkalaemia were included. The primary objective was to assess the evolution of serum potassium at 1, 3, 6, and 12 months after initiation of treatment. Secondary objectives included describing baseline patient characteristics, changes in RAASi and MRA therapy, and patiromer-related adverse events.</div></div><div><h3>Results</h3><div>A total of 59 patients were included. The baseline serum potassium level was 5.72 mmol/L, showing significant reductions at 1, 3, 6, and 12 months (5.02, 5.17, 5.11, and 5.01 mmol/L, respectively; all p &lt;<!--> <!-->0.001). Patiromer treatment enabled continuation of RAASi in 94.9% of patients and MRAs in 98.3%. The most frequent adverse events were gastrointestinal. Patiromer was discontinued in 8 patients (13.5%), with adverse effects accounting for half of these cases.</div></div><div><h3>Conclusions</h3><div>Our study provides real-world evidence on the effectiveness, safety, and RAASi/MRA maintenance potential of patiromer in patients with CKD and hyperkalaemia under routine care. In this setting, patiromer proved effective and well tolerated for managing hyperkalaemia and preserving RAASi/MRA therapy.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501454"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deficiencia de lecitina colesterol aciltransferasa con hallazgo de «cuerpos de cebra»: un reto diagnóstico frente a la sospecha de enfermedad de Fabry","authors":"Juan Enrique Rodriguez Mori ,&nbsp;Milagros del Pilar Dapello Jimenez ,&nbsp;Julia Sumire Umeres ,&nbsp;Roxana Maybor Lipa Chancolla","doi":"10.1016/j.nefro.2025.501444","DOIUrl":"10.1016/j.nefro.2025.501444","url":null,"abstract":"<div><div>Lecithin–cholesterol acyltransferase (LCAT) deficiency is a rare autosomal recessive disorder resulting from mutations in the LCAT gene, which leads to abnormal lipoprotein metabolism. This results in markedly reduced high-density lipoprotein cholesterol and the accumulation of lipoprotein X, leading to renal, corneal, and hemolytic damage. Two clinical variants have been described: familial LCAT deficiency (FLD) and fish-eye disease (FED).</div><div>We report the case of a 41-year-old male with a history of hypertension, tinnitus, and progressive hearing loss, who presented with bilateral corneal opacity since childhood. Laboratory studies revealed significant proteinuria (2.56<!--> <!-->g/24<!--> <!-->h), preserved renal function (creatinine 0.85<!--> <!-->mg/dl), mild anemia (Hb 10.2<!--> <!-->g/dl), and extremely low HDL cholesterol (1.3<!--> <!-->mg/dl). Renal biopsy showed focal segmental glomerulosclerosis and mesangial expansion. Electron microscopy demonstrated concentric lamellar inclusions known as “zebra bodies,” a finding typically associated with Fabry disease. However, α-galactosidase A activity was normal, and genetic testing for Fabry disease was negative. Further genetic analysis identified the variant c.757 p.(Gln253Argfs*11) in the LCAT gene, confirming the diagnosis of familial LCAT deficiency.</div><div>This case highlights the importance of differentiating LCAT deficiency from Fabry disease, given their overlapping clinical and histological features. Moreover, it represents the first description of “zebra bodies” in LCAT deficiency, emphasizing the diagnostic complexity and the need for a multidisciplinary approach to ensure accurate diagnosis and appropriate management.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501444"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masked alterations of glucose metabolism among patients awaiting kidney transplantation: Metabolic phenotyping and screening strategies","authors":"Elena Terán-García ,&nbsp;Lourdes Perez-Tamajón ,&nbsp;Celia R. Rodríguez-López ,&nbsp;Arminda Fariña-Hernández ,&nbsp;Estefanía Perez-Carreño ,&nbsp;Domingo Marrero-Miranda ,&nbsp;Cristian Acosta-Sorensen ,&nbsp;Antonia María de Vera-González ,&nbsp;Alejandra González-Delgado ,&nbsp;Ana Elena Rodríguez-Rodríguez ,&nbsp;Sagrario García-Rebollo ,&nbsp;Concepción Rodríguez-Adanero ,&nbsp;Alejandra Álvarez-González ,&nbsp;Ana Gonzalez-Rinne ,&nbsp;Antonio Manuel Rivero-González ,&nbsp;Manuel Luis Macia-Heras ,&nbsp;Aurelio P. Rodríguez-Hernández ,&nbsp;Eduardo De Bonis-Redondo ,&nbsp;Esteban Porrini ,&nbsp;Domingo Hernández-Marrero ,&nbsp;Armando Torres","doi":"10.1016/j.nefro.2025.501465","DOIUrl":"10.1016/j.nefro.2025.501465","url":null,"abstract":"<div><h3>Background</h3><div>Patients awaiting kidney transplantation are recommended to undergo systematic oral glucose tolerance tests (OGTT) to detect glucose metabolic alterations (GMA) that heighten the risk of posttransplant diabetes.</div></div><div><h3>Aims</h3><div>(a) To determine GMA prevalence and metabolic phenotypes; (b) assess optimal screening strategies for abnormal OGTT detection; and (c) evaluate one-year GMA trajectory through repeated OGTT during the waiting list period.</div></div><div><h3>Methods</h3><div>OGTTs were conducted on 182 wait-listed patients without diabetes, with 46 undergoing a repeat test after one year.</div></div><div><h3>Results</h3><div>Impaired glucose tolerance (IGT) was most common (23.1%). Undiagnosed diabetes (uDM) and isolated impaired fasting glucose (IFG) were observed in 6% and 4.4%, respectively. Patients with IGT/uDM exhibited decreased insulin secretion, while isolated IFG patients showed reduced insulin sensitivity. Abnormal OGTT correlated with statin therapy [OR 2.4 (1.17–4.9); <em>P</em> <!-->=<!--> <!-->0.02], fasting glucose [OR 1.03 (1.01–1.06); <em>P</em> <!-->=<!--> <!-->.02], and age [OR 1.03 (1–1.06); <em>P</em> <!-->=<!--> <!-->0.048]. Patients below age (51 years) and fasting glucose (100<!--> <!-->mg/dL) thresholds, not on statins, had lower odds of abnormal OGTT potentially reducing routine testing needs by 26%. Transition from normal to abnormal OGTT after one year correlated with higher baseline BMI [27.5<!--> <!-->kg/m² (IQR 25.6–31.7) vs. 24.1<!--> <!-->kg/m² (IQR 21.3–25.8); <em>P</em> <!-->=<!--> <!-->0.04], lower insulin sensitivity [Matsuda index 15.7 (IQR 11.4–24.5) vs. 22.9 (IQR 15.5–37); <em>P</em> <!-->=<!--> <!-->0.049], and statin use (75% vs. 32%; <em>P</em> <!-->=<!--> <!-->0.047).</div></div><div><h3>Conclusions</h3><div>One-third of wait-listed patients without manifest diabetes exhibit abnormal OGTT. Age, fasting glucose, and statin use increase risk. Patients below age and fasting glucose thresholds, without statins, have low abnormal OGTT likelihood, potentially reducing routine testing. Annual OGTT may benefit patients initially with normal results, if overweight/obese, or on statins.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501465"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concerns regarding glomerular disease in chronic graft versus host disease (cGVHD)","authors":"Karishma Bai ,&nbsp;Priyanka Bansari ,&nbsp;Sara Khan","doi":"10.1016/j.nefro.2025.501427","DOIUrl":"10.1016/j.nefro.2025.501427","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501427"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Más allá de los libros de texto: cilindros vacuolados como marcador emergente en el sedimento urinario","authors":"Oscar D. Pons-Belda ,&nbsp;Ana Calbet-Tur ,&nbsp;Paloma Livianos-Arias-Camison ,&nbsp;Emilia Moreno-Noguero ,&nbsp;Cassandra E. Puig-Hooper","doi":"10.1016/j.nefro.2025.501428","DOIUrl":"10.1016/j.nefro.2025.501428","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501428"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación de parámetros de ecografía renal con grado de enfermedad renal crónica","authors":"Verónica Rubio Menéndez ,&nbsp;Maite Rivera Gorrín","doi":"10.1016/j.nefro.2025.501450","DOIUrl":"10.1016/j.nefro.2025.501450","url":null,"abstract":"<div><div>Renal ultrasound is a fundamental tool in nephrological practice due to its non-invasive nature, accessibility, and low cost. Although it is widely used for the initial diagnosis of kidney diseases, its role as a follow-up method in chronic kidney disease (CKD) is less frequent.</div><div>This review explores the correlation between ultrasound parameters and CKD progression, considering that these may reflect kidney morphostructural changes.</div><div>Several ultrasound parameters are analyzed: renal length adjusted for height and corrected parenchymal thickness show a significant association with estimated glomerular filtration rate (eGFR). In contrast, cortical thickness and renal width present limitations and show poor correlation with eGFR.</div><div>Renal echogenicity, assessed against the liver and spleen, is related to irreversible renal damage and histological changes such as tubular atrophy and glomerulosclerosis, being one of the best ultrasound predictors of CKD progression. Of particular note is the CKD ultrasound score proposed by Yaprak, which integrates renal length, parenchymal thickness, and parenchymal echogenicity. This score has demonstrated high predictive ability to identify eGFR &lt;<!--> <!-->60<!--> <!-->mL/min, with an area under the curve of 0.829, sensitivity of 81%, and positive predictive value of 92%.</div><div>Finally, intrarenal Doppler parameters are described. The resistive index (RI) and peak systolic velocity (PSV) correlate with renal histological damage.</div><div>In conclusion, when appropriately applied and interpreted, renal ultrasound can provide valuable information for a more comprehensive assessment of CKD progression.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501450"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing chronic kidney disease care through risk prediction: A review of the kidney failure risk equation","authors":"Bernardo Marques da Silva ,&nbsp;Inês Silveira ,&nbsp;José António Lopes ,&nbsp;Joana Gameiro","doi":"10.1016/j.nefro.2025.501473","DOIUrl":"10.1016/j.nefro.2025.501473","url":null,"abstract":"<div><div>Chronic kidney disease (CKD) is a growing global health problem, with projections indicating a significant increase in its prevalence. The kidney failure risk equation (KFRE) has emerged as a valuable predictive tool to assess the risk of kidney failure in patients with CKD stages 3–5.</div><div>This narrative review presents a comprehensive analysis of the KFRE's development, validation, and clinical applications, and highlights its role in predicting disease progression, guiding nephrology referrals, and planning vascular access creation.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501473"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resultados de una encuesta nacional sobre el diagnóstico de la insuficiencia cardiaca en las consultas de nefrología: hora de actuar","authors":"María Marques Vidas ,&nbsp;Javier Diez ,&nbsp;Patricia de Sequera ,&nbsp;Alberto Ortiz ,&nbsp;Gregorio Romero-González ,&nbsp;María Fernanda Slon-Roblero ,&nbsp;Adriana Puente-García ,&nbsp;Borja Quiroga Gili","doi":"10.1016/j.nefro.2025.501433","DOIUrl":"10.1016/j.nefro.2025.501433","url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) is a common comorbidity with a major prognostic impact in patients with chronic kidney disease (CKD). However, screening and diagnostic practices for HF in nephrology clinics are not optimized. The aim was to assess routine clinical practice and identify gaps in HF diagnosis in the care of patients with CKD at any stage.</div></div><div><h3>Methods</h3><div>A nationwide survey of Spanish nephrologists was conducted using an electronic questionnaire. Data collection took place over a two-month period.</div></div><div><h3>Results</h3><div>A total of 73 centers completed the questionnaire. The estimated prevalence of HF among the patients seen was 44.1%, although only 30% of these cases were thought to be documented in the medical record. Although 55.4% of respondents reported performing active screening, the use of diagnostic tools such as echocardiography, natriuretic peptides, and electrocardiography was variable and often conditioned by the presence of symptoms.</div></div><div><h3>Conclusion</h3><div>These findings support a call to action based on the need to implement protocolized, multidisciplinary strategies to optimize HF diagnosis, as well as the early initiation of appropriate therapies for HF in patients with chronic kidney disease</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501433"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of glycaemic variability in type 2 diabetes mellitus patients on maintenance haemodialysis using continuous glucose monitoring","authors":"Asokan Arunkumar,&nbsp;Varadharajan Jayaprakash,&nbsp;Rajendran Rajasekar,&nbsp;Rishabh Gupta,&nbsp;Mathew Gerry George","doi":"10.1016/j.nefro.2025.501468","DOIUrl":"10.1016/j.nefro.2025.501468","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus is the leading cause of end-stage renal disease, accounting for approximately 40% of cases. Data on glycaemic metrics in diabetic population on maintenance haemodialysis is sparse. The role of continuous glucose monitoring in this population remains underexplored.</div></div><div><h3>Methods</h3><div>This prospective observational study aimed to comprehensively characterize glycaemic variability using continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing maintenance haemodialysis. 25 patients aged between 18 and 70 years with more than 3 months of dialysis vintage were included in the study. After collecting socio-demographic and clinical data, an ambulatory glucose profile sensor was applied to the patient's upper limb before starting their scheduled dialysis session. Sensors measured the interstitial fluid glucose every 15<!--> <!-->min, and a total of 96 readings were taken per day, continuously for 14 days (336<!--> <!-->h).</div></div><div><h3>Results</h3><div>For statistical analysis, the study population was broadly divided into 2 major groups, one which required insulin for their glycaemic management and the other requiring an oral hypoglycaemic agent, linagliptin. Statistical analysis was performed using SPSS software version 26.0 (IBM Corp., Armonk, NY). In both the groups, glycaemic excursion was observed, with dialysis days having high mean glucose values than non-dialysis days, and the observation was more prominent in the insulin-treated group. The mean glucose levels were lower in the nocturnal period in both the groups. It was noticed that the overall glycaemic variability, glycaemic variability in both dialysis and non-dialysis days were lower in linagliptin-treated group.</div></div><div><h3>Conclusion</h3><div>This study demonstrated significant differences in glycaemic variability based on antidiabetic treatment modality in haemodialysis population. Continuous glucose monitoring is an invaluable tool to study glycaemic metrics and guide therapy in haemodialysis population.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"46 3","pages":"Article 501468"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}